The Angiotensin Converting Enzyme 2/Ang-(1-7) Axis in the Heart

HomeCirculation ResearchVol. 103, No. 11The Angiotensin Converting Enzyme 2/Ang-(1-7) Axis in the Heart Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBThe Angiotensin Converting Enzyme 2/Ang-(1-7) Axis in the HeartA Role for Mas Communication? James A. StewartJr, Eric Lazartigues and Pamela A. Lucchesi James A. StewartJrJames A. StewartJr From the Center for Cardiovascular and Pulmonary Research (J.A.S., P.A.L.), Research Institute & The Heart Center, Nationwide Children's Hospital, Columbus, Ohio; and Department of Pharmacology and Experimental Therapeutics (E.L.), Louisiana State University Health Science Center, New Orleans. , Eric LazartiguesEric Lazartigues From the Center for Cardiovascular and Pulmonary Research (J.A.S., P.A.L.), Research Institute & The Heart Center, Nationwide Children's Hospital, Columbus, Ohio; and Department of Pharmacology and Experimental Therapeutics (E.L.), Louisiana State University Health Science Center, New Orleans. and Pamela A. LucchesiPamela A. Lucchesi From the Center for Cardiovascular and Pulmonary Research (J.A.S., P.A.L.), Research Institute & The Heart Center, Nationwide Children's Hospital, Columbus, Ohio; and Department of Pharmacology and Experimental Therapeutics (E.L.), Louisiana State University Health Science Center, New Orleans. Originally published21 Nov 2008https://doi.org/10.1161/CIRCRESAHA.108.189068Circulation Research. 2008;103:1197–1199For decades, the literature has been inundated with evidence of the important role of the renin–angiotensin system (RAS) in cardiac remodeling and function with most in the field familiar with this classic, dogmatic story. The protease renin is synthesized and released from the kidney and acts on a circulating inactive peptide, angiotensinogen, produced by the liver, giving rise to angiotensin (Ang) I. Ang I is then transformed into the biologically active octapeptide, Ang II, through enzymatic cleavage by angiotensin-converting enzyme (ACE).1 Ang II is the main effector molecule of the RAS, acting in an endocrine, autocrine/paracrine, and intracrine hormone pathway on cardiac cells. Ang II binds and activates G protein–coupled receptors, the angiotensin type 1 (AT1R) and angiotensin type 2 (AT2R) receptors, to mediate its actions. Activation of AT1R mediates most of the cardiovascular responses attributed to Ang II (ie, vasoconstriction, mitogenic and hypertrophic effects, fibrosis, inflammation, and fluid retention). In contrast, AT2R activation may cause opposing physiological responses that are increased in several disease processes.2Nearly 50 years after the discovery of ACE, a genomic based screening resulted in a characterization of ACE2, thus adding an unexpected twist into the well-known tale of the RAS.3,4 ACE2 is a carboxypeptidase that cleaves a single residue from Ang I to form Ang-(1-9), which is then converted to Ang-(1-7) by either ACE or neutral endopeptidases.3 This process is less efficient because of the requirement of 2 enzymatic processes. ACE2 also generates Ang-(1-7) from a single residue cleavage of Ang II with a higher affinity and thus may potentially be more physiologically relevant.Despite recent advances in our understanding of the ACE2/Ang II/Ang-(1-7) axis, the functional role of ACE2 in the heart is somewhat controversial. Crackower et al originally reported a progressive decrease in left ventricular contractile function in ACE2-null mice without significant changes in fibrosis, left ventricular and cardiac myocyte hypertrophy, or mean arterial pressure.5 Interestingly, whereas plasma and tissue levels of Ang II were increased, a decrease in blood pressure was only observed in 6-month-old male ACE2−/− homozygote mice but not in age-matched females or 3-month-old males. Conversely, Coffman and colleagues reported that ACE2 deletion enhanced the susceptibility to Ang II–induced hypertension but had no effect on cardiac structure or function.6 More recently, Raizada and colleagues used lentiviral-based ACE2 gene transfer to attenuate cardiac fibrosis and hypertrophy in SHR hypertensive rats7 and to improve left ventricular function and remodeling after myocardial infarction.8 Finally, Yamamoto et al9 reported that ACE2 deletion exacerbated pressure overload–induced cardiac dysfunction and remodeling that was associated with increased intracardiac Ang II levels and AT1R activation. The reasons for these discrepancies appear to reflect the genetic background of the mice used for ACE2 gene deletion,6 whether there was global versus tissue specific ACE2 manipulation, or whether cardiac responses were monitored under basal or pathophysiological conditions.Although it is now generally accepted that ACE2 plays a role in cardiac remodeling, the exact means by which ACE2 activity affords cardioprotection are unclear. Potential mechanisms include increased Ang II degradation and increased formation of Ang-(1-7) (Figure). The relative contribution of decreased Ang II levels versus increased Ang-(1-7) is difficult to decipher when ACE2 levels are manipulated or when the RAS pharmacologically blocked. To circumvent this issue, many studies have used chronic Ang-(1-7) treatment or infusion. For example, Santos et al were the first to show that increases in circulating Ang-(1-7) levels in transgenic rats afforded cardioprotection against isoproterenol.10 Ang-(1-7) treatment improves myocardial performance and survival in SHR rats following ischemia/reperfusion injury.11 Grobe et al12 reported that coinfusion of Ang-(1-7) blunted cardiac remodeling in response to chronic Ang II infusion. These studies established a cardioprotective role for Ang-(1-7) but did not demonstrate the direct effects of this peptide on the heart. Download figureDownload PowerPointFigure. Proposed ACE2-dependent mechanisms that antagonize the hypertrophic and fibrotic effects of Ang II in the myocardium. ACE2 can directly cleave Ang II to form Ang-(1-7). Ang-(1-7) activates the Mas receptor on cardiac fibroblasts and cardiac myocytes to initiate signaling pathways that antagonize AT1R-mediated tyrosine kinase cascades. In this simplified scenario, Ang-(1-7) increases SHP-2 tyrosine phosphatase activity to inactivate src-dependent signaling. Mas receptor activation also acts other pathways such as NO-AKT,16 potentially eliciting AT1R-independent effects.In this issue of Circulation Research, Mercure et al13 present an innovative approach to address the cardiac specific the role of increased Ang-(1-7) concentrations in vivo. Using a novel transgenic strategy to selectively overexpress Ang-(1-7) or Ang II in the heart, this study revealed no contractile defects under basal conditions at any of the ages examined. Using chronic, systemic Ang II infusion to induce hypertension yielded expected cardiac results in wild-type mice, including hypertrophy, fibrosis, expression of hypertrophic/profibrotic markers (atrial and brain natriuretic peptides, transforming growth factor [TGF]-β), and AT1R-mediated signaling. In contrast, transgenic cardiac-specific Ang-(1-7) overexpression concentrations reversed or dampened all of these events without significantly reducing blood pressure. These data unequivocally demonstrate that increased cardiac Ang-(1-7) elicits a direct cardioprotective effect even in the face of increased Ang II.The question that remains is how does Ang-(1-7) exert its actions? Most evidence points toward activation of the G protein–coupled Mas receptor, although interaction with, and inhibition of, the catalytic domain on ACE has been reported at higher doses (see Reudelhuber14 for a recent review). Mas receptor activation by Ang-(1-7) opposes many of the AT1 receptor-mediated actions (vasoconstriction, hypertrophy, fibrosis), thereby improving cardiac function and remodeling and attenuating heart failure.15,16 Ang-(1-7) binds to specific Mas receptors on cardiac fibroblasts to inhibit the fibrotic and hypertrophic effects of Ang II.17 Mas receptors are also localized to cardiac myocytes and activate NO production.18 The exact mechanisms by which Mas receptor activation antagonizes cardiac AT1R signaling are unclear. The data presented by Mercure et al13 suggest that Ang-(1-7)–dependent activation of the protein tyrosine phosphatase SHP-2 may attenuate AT1R -mediated activation of src and p38 mitogen-activated protein kinase. The requirement for Mas receptors was not determined, and it is also possible that Ang-(1-7) activates signaling cascades that affect cell function independently from AT1R pathways. However, because minimal cardiac effects of ACE2 deletion are observed under baseline conditions, it is tempting to speculate that a primary function of Ang-(1-7) may be to antagonize the effects of Ang II during pathophysiological insults.The observations of Mercure et al shed new light on the beneficial actions of the ACE2/Ang-(1-7) axis within the heart. The cardioprotective effects of ACE2 result from a one-two punch involving direct degradation of Ang II and inhibition of AT1R-mediated signaling via Ang-(1-7)/Mas receptor activation. Although further clarification of the role of Mas in the direct effects of Ang-(1-7) on the heart are warranted, the findings reported by Mercure et al13 indicate that Ang-(1-7) is a bona fide therapeutic target for cardiovascular disease. In this regard, an orally active Ang-(1-7) analog, AVE0991, mimics the cardioprotective effects of Ang-(1-7).17 This has important clinical implications because the use of ACE inhibitors and angiotensin receptor blockers, although effective in reducing cardiovascular morbidity mortality, has failed to stem the increasing prevalence of hypertensive and coronary artery–related heart disease.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.Sources of FundingSupported by NIH grant HL05604 (to P.A.L.).DisclosuresNone.FootnotesCorrespondence to Pamela A. Lucchesi, PhD, Center for Cardiovascular and Pulmonary Research Nationwide Children's Hospital, 700 Children's Dr, W303, Columbus, OH 43205. E-mail [email protected] References 1 Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006; 86: 747–803.CrossrefMedlineGoogle Scholar2 de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000; 52: 415–472.MedlineGoogle Scholar3 Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res. 2000; 87: e1–e9.LinkGoogle Scholar4 Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000; 275: 33238–33243.CrossrefMedlineGoogle Scholar5 Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417: 822–828.CrossrefMedlineGoogle Scholar6 Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N, Haystead TA, Donoghue M, Breitbart RE, Acton SL, Rockman HA, Coffman TM. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest. 2006; 116: 2218–2225.CrossrefMedlineGoogle Scholar7 Diez-Freire C, Vazquez J, Correa de Adjounian MF, Ferrari MF, Yuan L, Silver X, Torres R, Raizada MK. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics. 2006; 27: 12–19.CrossrefMedlineGoogle Scholar8 Der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, Katovich MJ, Raizada MK. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension. 2008; 51: 712–718.LinkGoogle Scholar9 Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, Kaibe M, Tatara Y, Shiota A, Sugano S, Takeda S, Rakugi H, Ogihara T. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension. 2006; 47: 718–726.LinkGoogle Scholar10 Santos RA, Ferreira AJ, Nadu AP, Braga AN, de Almeida AP, Campagnole-Santos MJ, Baltatu O, Iliescu R, Reudelhuber TL, Bader M. Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics. 2004; 17: 292–299.CrossrefMedlineGoogle Scholar11 Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol. 2006; 290: H684–H691.CrossrefMedlineGoogle Scholar12 Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol. 2007; 292: H736–H742.CrossrefMedlineGoogle Scholar13 Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, Santos RAS, Walther T, Touyz RM, Reudelhuber TL. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res. 2008; 103: 1319–1326.LinkGoogle Scholar14 Reudelhuber TL. A place in our hearts for the lowly angiotensin 1-7 peptide? Hypertension. 2006; 47: 811–815.LinkGoogle Scholar15 Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC, Bader M, Alenina N, Kitten GT, Ferreira AJ. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension. 2006; 47: 996–1002.LinkGoogle Scholar16 Tallant EA, Diz DI, Ferrario CM. State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension. 1999; 34: 950–957.CrossrefMedlineGoogle Scholar17 Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol. 2005; 289: H2356–H2363.CrossrefMedlineGoogle Scholar18 Dias-Peixoto MF, Santos RA, Gomes ER, Alves MN, Almeida PW, Greco L, Rosa M, Fauler B, Bader M, Alenina N, Guatimosim S. Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension. 2008; 52: 542–548.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Amirfakhryan H and safari F (2021) Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement, Hellenic Journal of Cardiology, 10.1016/j.hjc.2020.05.007, 62:1, (13-23), Online publication date: 1-Jan-2021. De A, Dash M, Tiwari A and Sinha A (2021) Malaria, COVID-19 and angiotensin-converting enzyme 2: what does the available population data say?, Open Biology, 10.1098/rsob.210213, 11:10, Online publication date: 1-Oct-2021. Altable M and de la Serna J (2020) Cerebrovascular disease in COVID-19: Is there a higher risk of stroke?, Brain, Behavior, & Immunity - Health, 10.1016/j.bbih.2020.100092, 6, (100092), Online publication date: 1-Jul-2020. Santos R, Sampaio W, Alzamora A, Motta-Santos D, Alenina N, Bader M and Campagnole-Santos M (2018) The ACE2/Angiotensin-(1–7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1–7), Physiological Reviews, 10.1152/physrev.00023.2016, 98:1, (505-553), Online publication date: 1-Jan-2018. Zhang X, Cheng H, Zhou P, Kitzman D, Ferrario C, Li W and Cheng C (2017) Cellular basis of angiotensin-(1-7)-induced augmentation of left ventricular functional performance in heart failure, International Journal of Cardiology, 10.1016/j.ijcard.2017.01.071, 236, (405-412), Online publication date: 1-Jun-2017. Kim H, Kim S, Baek S and Kwon S (2016) Pivotal Cytoprotective Mediators and Promising Therapeutic Strategies for Endothelial Progenitor Cell-Based Cardiovascular Regeneration, Stem Cells International, 10.1155/2016/8340257, 2016, (1-14), . Liu D, Chen Y, Zhang P, Zhong J, Jin L, Zhang C, Lin S, Wu S and Yu H (2016) Association between circulating levels of ACE2-Ang-(1–7)-MAS axis and ACE2 gene polymorphisms in hypertensive patients, Medicine, 10.1097/MD.0000000000003876, 95:24, (e3876), Online publication date: 1-Jun-2016. Zhou P, Cheng C, Li T, Ferrario C and Cheng H (2015) Modulation of cardiac L-type Ca 2+ current by angiotensin-(1-7): normal versus heart failure , Therapeutic Advances in Cardiovascular Disease, 10.1177/1753944715587424, 9:6, (342-353), Online publication date: 1-Dec-2015. Xiao X, Zhang C, Ma X, Miao H, Wang J, Liu L, Chen S, Zeng R, Chen Y and Bihl J (2015) Angiotensin-(1–7) counteracts angiotensin II-induced dysfunction in cerebral endothelial cells via modulating Nox2/ROS and PI3K/NO pathways, Experimental Cell Research, 10.1016/j.yexcr.2015.06.010, 336:1, (58-65), Online publication date: 1-Aug-2015. Benter I, Yousif M, Juggi J and Akhtar S (2014) The Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Receptor Axis: A Potential Target for Treating Diabetic Cardiovascular Disease Diabetic Cardiomyopathy, 10.1007/978-1-4614-9317-4_22, (349-357), . Bhatia K, Zimmerman M and Sullivan J (2013) Sex Differences in Angiotensin-Converting Enzyme Modulation of Ang (1-7) Levels in Normotensive WKY Rats, American Journal of Hypertension, 10.1093/ajh/hps088, 26:5, (591-598), Online publication date: 1-May-2013. Whitaker A and Molina P (2013) Angiotensin (1-7) contributes to nitric oxide tonic inhibition of vasopressin release during hemorrhagic shock in acute ethanol intoxicated rodents, Life Sciences, 10.1016/j.lfs.2013.08.020, 93:17, (623-629), Online publication date: 1-Oct-2013. Tikellis C and Thomas M (2012) Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease, International Journal of Peptides, 10.1155/2012/256294, 2012, (1-8), Online publication date: 20-Mar-2012. Tikellis C, Pickering R, Tsorotes D, Du X, Kiriazis H, Nguyen-Huu T, Head G, Cooper M and Thomas M (2012) Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes, Clinical Science, 10.1042/CS20110668, 123:8, (519-529), Online publication date: 1-Oct-2012. Whitaker A, Sulzer J and Molina P (2011) Augmented central nitric oxide production inhibits vasopressin release during hemorrhage in acute alcohol-intoxicated rodents, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 10.1152/ajpregu.00035.2011, 301:5, (R1529-R1539), Online publication date: 1-Nov-2011. Tikellis C, Bernardi S and Burns W (2011) Angiotensin-converting enzyme 2 is a key modulator of the renin–angiotensin system in cardiovascular and renal disease, Current Opinion in Nephrology and Hypertension, 10.1097/MNH.0b013e328341164a, 20:1, (62-68), Online publication date: 1-Jan-2011. Shah A, Gul R, Yuan K, Gao S, Oh Y, Kim U and Kim S (2010) Angiotensin-(1–7) stimulates high atrial pacing-induced ANP secretion via Mas/PI3-kinase/Akt axis and Na + /H + exchanger , American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00608.2009, 298:5, (H1365-H1374), Online publication date: 1-May-2010. Sarkar S and Sen R (2022) Insights into Cardiovascular Defects and Cardiac Epigenome in the Context of COVID-19, Epigenomes, 10.3390/epigenomes6020013, 6:2, (13) Pérez-Bermejo M, Peris-Ochando B and Murillo-Llorente M (2021) COVID-19: Relationship and Impact on Breastfeeding—A Systematic Review, Nutrients, 10.3390/nu13092972, 13:9, (2972) November 21, 2008Vol 103, Issue 11 Advertisement Article InformationMetrics https://doi.org/10.1161/CIRCRESAHA.108.189068PMID: 19028917 Originally publishedNovember 21, 2008 PDF download Advertisement